Therefore, it is evident that EZH2 can either act as an oncogene in B-cell and NKT lymphomas, presenting increased activity or function as a tumor suppressor in MDSs and T-ALL. This evidence concerns the gene EZH2 and acute lymphoblastic leukemia.